Dr. Reddy's LaboratoriesRDY
紐約證券 · USD
13.94
-0.28
(-1.97%)
收盤 08/02 03:59 (UTC+8)
盤後
0
0
(0%)
08/02 03:59 (UTC+8)
Dr. Reddy's LaboratoriesRDY
13.94
-0.28
(-1.97%)
財務數據
損益表
- 629.68
- 673.84
- 688.02
- 721.48
- 708.30
- 767.27
- 801.62
- 835.86
- 850.60
- 854.52
- -6.99
- 7.01
- 2.10
- 4.86
- -1.83
- 8.33
- 4.48
- 4.27
- 1.76
- 0.46
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | 2023/Q2 | 2023/Q1 | |
營業收入淨額 | 85,452,000 | 85,060,000 | 83,586,000 | 80,162,000 | 76,727,000 | 70,830,000 | 72,148,000 | 68,802,000 | 67,384,000 | 62,968,000 |
營業成本 | 36,825,000 | 37,797,000 | 34,534,000 | 32,393,000 | 30,383,000 | 29,347,000 | 29,945,000 | 28,434,000 | 27,831,000 | 26,971,000 |
營業毛利 | 48,627,000 | 47,263,000 | 49,052,000 | 47,769,000 | 46,344,000 | 41,483,000 | 42,203,000 | 40,368,000 | 39,553,000 | 35,997,000 |
營業費用 | 31,785,000 | 29,915,000 | 30,344,000 | 29,724,000 | 28,802,000 | 28,205,000 | 25,297,000 | 22,883,000 | 21,906,000 | 22,938,000 |
研發費用 | 6,244,000 | 7,258,000 | 6,658,000 | 7,271,000 | 6,193,000 | 6,877,000 | 5,565,000 | 5,447,000 | 4,984,000 | 5,366,000 |
推銷及管理費用 | 23,181,000 | 24,055,000 | 24,117,000 | 23,007,000 | 20,887,000 | 20,476,000 | 20,228,000 | 18,795,000 | 17,702,000 | 17,992,000 |
非經常性項目費用 | - | - | - | - | - | - | - | - | - | - |
其他營業費用 | -106,000 | -1,398,000 | -431,000 | -554,000 | -82,000 | 852,000 | -496,000 | -1,359,000 | -780,000 | -420,000 |
營業利益 | 16,842,000 | 17,348,000 | 18,708,000 | 18,045,000 | 17,542,000 | 13,278,000 | 16,906,000 | 17,485,000 | 17,647,000 | 13,059,000 |
其他收入及費用 | - | - | - | - | - | - | - | - | - | - |
利息費用 | 830,000 | 656,000 | 818,000 | 757,000 | 598,000 | 593,000 | 394,000 | 353,000 | 371,000 | 354,000 |
稅前純益 | 19,047,000 | 20,054,000 | 18,742,000 | 19,167,000 | 18,821,000 | 16,016,000 | 18,257,000 | 19,134,000 | 18,463,000 | 13,255,000 |
所得稅 | 4,951,000 | 4,182,000 | 4,704,000 | 5,752,000 | 4,901,000 | 2,946,000 | 4,468,000 | 4,334,000 | 4,438,000 | 3,663,000 |
稅後純益 | 14,178,000 | 15,938,000 | 14,133,000 | 12,553,000 | 13,920,000 | 13,070,000 | 13,789,000 | 14,800,000 | 14,025,000 | 9,592,000 |
基本每股稅後盈餘(元) | 17.04 | - | 16.96 | 15.07 | 83.60 | 78.66 | 82.80 | 17.79 | 84.38 | 57.79 |
稀釋每股稅後盈餘(元) | 17.02 | - | 16.94 | 15.05 | 83.45 | 78.53 | 82.70 | 17.76 | 84.22 | 57.68 |
基本平均股數(千股) | 832042.00 | - | 833313.00 | 166609.00 | 166507.00 | 166514.00 | 166533.00 | 166485.00 | 166209.00 | 166136.00 |
稀釋平均股數(千股) | 833019.00 | - | 834297.00 | 166609.00 | 166806.00 | 166789.00 | 166735.00 | 166485.00 | 166528.00 | 166452.00 |
還原基本每股稅後盈餘(元) | 17.04 | - | 16.96 | 3.01 | 16.72 | 15.73 | 16.56 | 3.56 | 16.88 | 11.56 |
還原稀釋每股稅後盈餘(元) | 17.02 | - | 16.94 | 3.01 | 16.69 | 15.71 | 16.54 | 3.55 | 16.84 | 11.54 |
還原基本平均股數(千股) | 832,042 | - | 833,313 | 833,046 | 832,535 | 832,570 | 832,669 | 832,429 | 831,049 | 830,680 |
還原稀釋平均股數(千股) | 833,019 | - | 834,297 | 833,046 | 834,032 | 833,948 | 833,675 | 832,429 | 832,640 | 832,264 |
EBITDA(千元) | 24,724,000 | 25,330,000 | 24,374,000 | 23,037,000 | 23,229,000 | 20,322,000 | 22,421,000 | 23,276,000 | 22,403,000 | 16,798,000 |